Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05581004Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Oct 2022
- Primary completion
- Jul 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 1, open-label trial of enzelkitug in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 9 more (4 arms), sponsored by Genentech. Primary endpoints: Dose-limiting Toxicities at 21 days and Treatment-emergent Adverse Events at 52 months. Started Oct 2022; status: active, not recruiting.
02
Drugs
enzelkitug
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanomatriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05581004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581004.